Alzheimer's Disease — MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)
Citation(s)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of MK0249 for the Symptomatic Treatment of Alzheimer's Disease